Detalles de la búsqueda
1.
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents.
Cancer Immunol Immunother
; 71(8): 1823-1835, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34984538
2.
Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
Int J Mol Sci
; 23(20)2022 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36293498
3.
Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients.
Biomedicines
; 12(5)2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38790920
4.
Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors.
Cancers (Basel)
; 16(9)2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38730712
Resultados
1 -
4
de 4
1
Próxima >
>>